Clinico-Pharmacological and Clinical Basis of Multiplicity of Intake of Novel Oral Anticoagulants

In this review we present comparison of pharmacokinetics of novel oral anticoagulants (NOAC) dabigatran, rivaroxaban, apixaban, and edoxaban, principles of selection of a regimen of their dosing for phase III clinical trials in patients with atrial fibrillation. Multiplicity of administration of NOAC depends on required level of anticoagulation, ability to maintain anticoagulation for 24 hours, relationship between minimal and maximal levels of equilibrium concentrations, efficacy and safety. Once a day administration of some drugs of this group is reasonable from positions of clinical pharmacology. It can provide not only better adherence to treatment but greater safety relative to development of bleeding.

антикоагулянты, ривароксабан, дабигатран, апиксабан, эдоксабан, фармакокинетика, фармакодинамика, клинические исследования, anticoagulants, rivaroxaban, dabigatran, apixaban, edoxaban, pharmacokinetics, pharmacodynamics, clinical trials

1. Paulus Kirchhof, Stefano Benussi, Dipak Kotecha et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.

2. Kearon C., Akl E. A., Omelas J. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016;149:315-352.

3. Сулимов В. А., Напалков Д. А., Соколова А. А. Сравнительная эффективность и безопасность новых пероральных антикоагулянтов. Рациональная фармакотерапия в кардиологии 2013;9 (4):433-438.

4. Amish N. et al. Management of Patients on Non - Vitamin K. Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting. Circulation 2017;135.

5. Eduardo Sabaté. Adherence to long-term therapies: evidence for action. World Health Organization, 2003. http://www.who.int / chp /knowledge /publications / adherence_ report/en/

6. Cramer J., Roy A., Burrell A. et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11 (1):44-47.

7. Osterberg L., Blaschke T. Adherence to medication. N. Engl J. Med 2005;353 (5):487-497.

8. Crivera C., Nielson W., Bookhart B. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin 2015;31 (10):1889-1895.

9. Renda G., De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 2013;59 (3-4):53-62.

10. Hu Z., Parker R., Herring V., Laizure S. Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem 2013;405 (5):1695-1704.

11. Eriksson B., Dahl O., Buller H. et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb Haemost 2005;3:103-111.

12. Eriksson B., Dahl O., Ahnfelt L. et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb Haemost 2004;2:1573-1580.

13. Raghavan N., Frost C., Yu Z. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81.

14. Camm A., Bounameaux H. Edoxaban: a new oral direct Factor Xa inhibitor. Drugs 2011;71:1503-1526.

15. Ogata K., Mendell-Harary J., Tachibana M., Masumoto H., Oguma T., Kojima M. et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J. Clin Pharmacol 2010;50:743-753.

16. Mueck W., Eriksson B., Bauer K. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in patients undergoing major orthopedic surgery. Clin Pharmacokinetic 2008;47:203-216.

17. Renda G., De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 2013;59 (3-4):53-62.

18. Buxton I. Pharmacokinetics and pharmacodynamics. In: Brunton L., editor. The dynamics of drug absorption, distribution, action, and elimination. Goodman & Gilman's The pharmacological basis of therapeutics, 11 ed. McGraw Hill; 2006. p. 1-39.

19. Kubitza D., Becka M., Voith B. et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-421.

20. Mueck W., Borris L., Dahl O. et al. Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-461.

21. Agnelli G., Gallus A., Goldhaber S. et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deepvein thrombosis) study. Circulation 2007;116:180-187.

22. Büller H., Lensing A., Prins M. et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood 2008;112:2242-2247.

23. Fiessinger J., Huisman M., Davidson B. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-689.

24. Van Gogh Investigators, Büller H., Cohen A. et al. Idraparinux versus standard therapy for venous thromboembolic disease. N. Engl J. Med 2007;357:1094-1104.

25. Caplan. Caplan's Stroke: A Clinical Approach, Fourth Edition 2009. In: Chapter 5. Treatment. Saunders Elsevier, Philadelphia, PA, USA.

26. Eriksson B., Dahl O., Ahnfelt L. et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatranetexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb Haemost 2004;2:1573-1580.

27. Reilly P., Lehr T., Haertter S. et al.; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J. Am Coll Cardiol 2014;63 (4):321-328.

28. Sinigoj P. et al. Dabigatran Concentration: Variability and Potential Bleeding Prediction In «Real-Life» Patients With Atrial Fibrillation. Basic Clin Pharmacol Toxicol 2015;117 (5):323-329.

29. Owada S., Tomita H., Kinjo T. et al. CHA2DS2-VASc and HASBLED scores and activated partial thromboplastin time for prediction of high plasmaconcentration of dabigatran at trough. Thromb Res 2015;135 (1):62-67.

30. Lassen M., Davidson B., Gallus A. et al. The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5:2368-2375.

31. Lassen M., Gallus A., Raskob G. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-2498.

32. Lopes R., Alexander J., Al-Khatib S. et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-339.

33. Granger C., Alexander J., McMurray J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.

34. Connolly S., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.

35. Weitz J., Connolly S., Patel I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104:633-641.

36. Connolly S., Ezekowitz M., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.

37. Patel M., Mahaffey K., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.

38. Laliberte F., Nelson W., Lefebvre P. et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-690.

39. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005;353 (5):487-497.

40. Coleman C., Roberts M., Sobieraj D. et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012;28:669-680.

41. Laliberté F. еt al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 2013;6 (3):213-224. doi: 10.1007/s40271-013-0020-5.

42. Mc Horney C., Crivera C., Laliberté F. et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin 2015;31 (12):2167-2173.

43. Camm A., Amarenco P., Haas S. et al. XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37 (14):1145-1153.

44. Hecker J., Marten S., Keller L. et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016;115 (5):939-949.

45. Mc Horney et al., Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrillation. American College of Cardiology Conference 2017, Washington, DC, USA, 17-19 March 2017; Poster 1252-1306.